Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
F Cappuzzo, A Morabito, N Normanno, P Bidoli… - Lung Cancer, 2016 - Elsevier
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …
Survival outcomes in EGFR mutation-positive lung cancer patients treated with gefitinib until or beyond progression
FV Moiseyenko, VM Moiseyenko… - Oncology Research …, 2016 - karger.com
Background: Discontinuation of gefitinib treatment is often accompanied by a disease flare.
Some studies have demonstrated a benefit of the use of epidermal growth factor receptor …
Some studies have demonstrated a benefit of the use of epidermal growth factor receptor …
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non–small-cell lung cancer who previously responded to gefitinib
T Koizumi, T Agatsuma, K Ikegami, T Suzuki… - Clinical lung cancer, 2012 - Elsevier
Introduction Salvage treatment for acquired resistance to epidermal growth factor receptor
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
SW Lim, S Park, Y Kim, JH Cho, SE Park, H Lee… - Lung Cancer, 2018 - Elsevier
Objectives Several studies have demonstrated the promise of continuation of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) beyond progression in patients …
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) beyond progression in patients …
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC cancer, 2007 - Springer
Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
[HTML][HTML] Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression …
Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib …
Background Optimum management strategies for patients with advanced non-small-cell
lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are …
lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are …
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of …
Purpose Efficacy of gefitinib therapy strongly depends on epidermal growth factor receptor
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …
(EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). However …
Efficacy and safety of gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib followed by second-line …
Y Song, YL Wu, LJ Cao, JH Chen, ZY Ma… - American Journal of …, 2019 - journals.lww.com
Objective: There is no standard care for advanced non–small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …
patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study …